Myriad Announces Launch of "Go Green" Sustainability Initiative In Support of Earth Day
April 19 2018 - 9:05AM
Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in
personalized medicine, today announced the launch of its new Go
Green sustainability initiative. As part of the initiative, Myriad
is initially focused on promoting increased recycling and reducing
material waste used throughout the company. Myriad has now launched
several initiatives and employee incentive programs to try and
increase its total volume of recyclable materials by over 100% and
reduce material waste by 20% by the end of fiscal year 2019. Beyond
the initial focus of material waste reduction, the company intends
to introduce a number of additional environmental programs over the
next several years in areas such as reducing greenhouse gas
emissions, reducing water use, reducing power consumption and
promoting employee health and safety.
“I am extremely proud of the launch of the Go Green initiative
which is reflective of our values as a company and Myriad’s
dedication to improving the world which we live in,” said Mark C.
Capone, president and CEO, Myriad Genetics. “Being a responsible
steward is an integral part of the DNA of our company.”
As part of Earth Day, Myriad Genetics employees will also be
participating in local community service projects including
volunteer work at the University of Utah’s Red Butte Gardens and
facilitating the collection of hard-to-recycle items such as
fluorescent light bulbs. Throughout the month of May, employees
will also take part in education about waste reduction and look for
ways to incorporate sustainable practices into their daily
work.
“At Myriad caring is part of who we are as an organization and
beyond caring about patients we care deeply for the local community
and environment where we work, said Steve Beus, head of the Myriad
Go Green Team. “We strongly believe this initiative will have a
significant impact on our environmental footprint as a company and
benefit the beautiful Utah community in which we work and
live.”
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
five strategic imperatives: build upon a solid hereditary
cancer foundation, growing new product volume, expanding
reimbursement coverage for new products, increasing RNA kit revenue
internationally and improving profitability with Elevate
2020. For more information on how Myriad is making a
difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore and
Prolaris are trademarks or registered trademarks of Myriad
Genetics, Inc. or its wholly owned subsidiaries in the United
States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to the Company’s efforts to increase its total
volume of recyclable materials by over 100% and reduce material
waste by 20% by the end of fiscal year 2019; the company’s
intention to introduce a number of additional environmental
programs over the next several years in areas such as reducing
greenhouse gas emissions, reducing water use, reducing power
consumption and promoting employee health and safety; Company
employees participating in local community service projects
including volunteer work at the University of Utah’s Red Butte
Gardens, facilitating the collection of hard-to-recycle items such
as fluorescent light bulbs, and taking part in education about
waste reduction and looking for ways to incorporate sustainable
practices into their daily work; this initiative having a
significant impact on the Company’s environmental footprint and
benefiting the Utah community; and the Company’s strategic
directives under the caption “About Myriad Genetics.” These
“forward-looking statements” are based on management’s current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those described or implied in the
forward-looking statements. These risks include, but are not
limited to: the risk that sales and profit margins of our existing
molecular diagnostic tests and pharmaceutical and clinical services
may decline or will not continue to increase at historical rates;
risks related to our ability to transition from our existing
product portfolio to our new tests; risks related to changes in the
governmental or private insurers’ reimbursement levels for our
tests or our ability to obtain reimbursement for our new tests at
comparable levels to our existing tests; risks related to increased
competition and the development of new competing tests and
services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services tests and any future tests are terminated or
cannot be maintained on satisfactory terms; risks related to delays
or other problems with operating our laboratory testing facilities;
risks related to public concern over our genetic testing in general
or our tests in particular; risks related to regulatory
requirements or enforcement in the United States and foreign
countries and changes in the structure of the healthcare system or
healthcare payment systems; risks related to our ability to obtain
new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire, including but not limited to our acquisition of Assurex,
Sividon and the Clinic; risks related to our projections about the
potential market opportunity for our products; the risk that we or
our licensors may be unable to protect or that third parties will
infringe the proprietary technologies underlying our tests; the
risk of patent-infringement claims or challenges to the validity of
our patents; risks related to changes in intellectual property laws
covering our molecular diagnostic tests and pharmaceutical and
clinical services and patents or enforcement in the United States
and foreign countries, such as the Supreme Court decision in the
lawsuit brought against us by the Association for Molecular
Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; the risk that we may be unable to comply with
financial operating covenants under our credit or lending
agreements; the risk that we will be unable to pay, when due,
amounts due under our credit or lending agreements; and other
factors discussed under the heading “Risk Factors” contained in
Item 1A of our Annual report on Form 10-K for the fiscal year ended
June 30, 2016, which has been filed with the Securities and
Exchange Commission, as well as any updates to those risk factors
filed from time to time in our Quarterly Reports on Form 10-Q or
Current Reports on Form 8-K.
Media
Contact: |
|
Ron
Rogers(801) 584-3065rrogers@myriad.com |
|
Investor
Contact: |
|
Scott
Gleason(801) 584-1143sgleason@myriad.com |
|
|
|
|
|
|
|
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024